Feed ZTS
ZT

Zoetis

ZTS · NYSE

$73.41 -0.35% (-$0.26)
1M +0.96%
Market Cap $30.8B
P/E Ratio 11.76x
Div. Yield 2.85%
ROE 69.25%

Bulios Fair Price

$87.89

19.7% upside

Current Price

$73.41

Undervalued Fair Value Overvalued

According to Bulios Fair Price, ZTS is currently undervalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Strong
7/9
Valuation
75 /100
Cheap
P/FCF 13.01x
P/E 11.76x
P/B 9.78x
Growth
58 /100
Stable
FCF growth 19.85%
EPS growth 10.27%
Book val. growth 8.89%
Profitability
100 /100
Strong
Op. margin 37.00%
Gross margin 70.87%
FCF margin 24.86%
Quality
93 /100
Excellent
ROA 17.35%
ROIC 21.63%
Asset turnover 0.63x
Debt
57 /100
Moderate
Int. coverage 14.39x
Debt/Equity 2.93x
Net debt/EBITDA 2.00x
Stability
100 /100
Stable
EPS volatility 2.52%
Beta 0.73x
Profitable years 6

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about ZTS
Online

About the company

Zoetis Inc. (ZTS) is a global pharmaceutical company focused on animal health, headquartered in the USA. The company specializes in the development, manufacturing, and sale of medications and vaccines for animals. Zoetis provides a wide range of products for animal treatment and disease prevention in both domestic pets and livestock. Their portfolio includes medications for animals such as dogs, cats, cattle, pigs, poultry, and others. With its research, innovations, and global presence, Zoetis has gained a leading position in the field of animal health. The company focuses on improving the quality of life for animals and supports animal health worldwide. Zoetis Inc. (ZTS) shares can be an attractive investment opportunity for investors monitoring the animal health sector and valuing stability and long-term growth in this industry.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Kristin C. Peck

Employees

14,500

Headquarters

Parsippany

Upcoming events

03 NOV

Earnings

Upcoming earnings report

48d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.